Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Alnylam discussed confidence in its reset 2026 TTR-franchise revenue outlook at the Wells Fargo Healthcare Conference, with investor focus on AMVUTTRA's cardiomyopathy launch trajectory. Management noted the cardiomyopathy indication had been launched about 18 months earlier, following AMVUTTRA's existing approval in hereditary polyneuropathy. The excerpt provides no updated revenue guidance, sales figures, or material clinical data, leaving the near-term investment readthrough neutral.

Analysis

This is not a clean incremental fundamental catalyst: the available excerpt contains management framing around the post-reset trajectory but no independently verifiable patient-start, persistence, payer-access, or revised-guidance detail. ALNY’s valuation sensitivity is therefore concentrated in whether cardiomyopathy adoption converts from initial prescriber enthusiasm into durable quarterly net-product-sales growth; even modest deviations in treated-patient growth can drive disproportionate multiple movement given the franchise’s importance to the earnings-power narrative.

The key competitive variable over the next 1-3 months is not simply market growth but share capture versus PFE’s Vyndaqel/Vyndamax franchise and BridgeBio’s acoramidis/Attruby. A lower-cost oral alternative can pressure gross-to-net and delay treatment switching even if the RNAi mechanism retains clinical differentiation. Over 6-18 months, successful expansion of the treatable cardiomyopathy population would support ALNY’s platform multiple, while slower diagnosis, restrictive utilization management, or evidence of lower persistence would shift the market toward viewing the asset as a narrower specialty franchise.

Consensus may be too focused on launch-quarter volatility and insufficiently focused on the lag between account activation, reimbursement approval, and recurring dosing. That said, management confidence alone is not a reason to add risk after a guidance reset; the thesis is falsified if the next reported quarter fails to show sequential acceleration in new patient starts and maintained net pricing, or if full-year guidance is revised again.

Key Decisions for Investors

• Maintain ALNY as a watch-list long rather than initiate on this conference appearance; require next-quarter evidence of accelerating cardiomyopathy new starts, stable persistence, and no further reduction to franchise guidance before adding exposure.
• For an existing ALNY long, use a defined risk trigger: reduce if management again revises annual revenue expectations or attributes softness to payer restrictions, patient discontinuation, or competitive switching rather than timing of enrollments.
• Monitor a relative-value setup of long ALNY versus short PFE only after prescription/share data demonstrate sustained displacement of tafamidis; without those data, the pair lacks an identifiable near-term catalyst and PFE’s diversified earnings base weakens the hedge.
• Track BridgeBio (BBIO) commercial metrics and ATTRibute-CM adoption signals as the most relevant competitive read-through. Evidence that Attruby wins broad formulary preference or requires materially lower patient out-of-pocket cost would be a negative alert for ALNY’s medium-term net-price and market-share assumptions.